Altria reported a solid performance in the first half of 2023 despite lower net revenues, partially offset by higher revenue in the oral tobacco segment
Sales of HeatSticks could ironically end up benefitting from a US legal battle lost by their manufacturer Philip Morris and other leading tobacco companies
US tobacco giant Altria is to pay $235m to settle at least 6,000 state and federal cases related to Juul, ending most of the suits it is still facing in relation to the e-cigarette company
US tobacco giant Altria closed the first quarter of 2023 with a slight fall in its net revenues compared with the same period last year, while it recorded an increase in its adjusted diluted earnings per share (EPS)
Altria has swapped its 35% stake in Juul Labs for heated tobacco intellectual property rights, ending an investment which plummeted in value from $12.8bn to only $250m in just over four years
The significance Big Tobacco companies are placing on novel tobacco products is demonstrated by the continued international expansion many are undertaking
Altria is reported to be in advanced talks to buy e-cigarette company Njoy for around $2.75bn.No deal has been finalised, but an official announcement is possible by the end of the week
Fewer people smoking has led to US cigarette maker Altria continuing to see a decrease in revenue over the third quarter of 2022, partially offset by higher net revenues in the oral tobacco products segment
Tobacco giants Altria and JT Group are to form a joint venture to market in the US heated tobacco stick products owned and developed by either company
Altria saw $5.9bn in revenue in Q1 2022 – a decrease from both Q4 2021 ($6.25bn) and by 2.4% compared to Q1 2021
Tobacco giant Altria’s net revenues slightly declined in 2021, partially offset by growth in the company’s oral tobacco products segment
Altria posted a 4.7% revenue decline in the third quarter of the year, mainly driven by the continuing poor performance of its smokable segment but neutralised by the growth of its oral products in the US
The US Food and Drug Administration (FDA) has issued marketing authorisation for four mint-flavoured oral tobacco products that were withdrawn from the US market in 2019
A judge of the US International Trade Commission (ITC) believes Philip Morris International (PMI)’s Iqos heated tobacco sticks infringe patents owned by British American Tobacco (BAT)
Altria has confirmed its full-year guidance for 2021 and full acquisition of its nicotine pouches business despite a dip in total company earnings for the first quarter of the year
A patent infringement hearing at the US International Trade Commission (ITC) could result in Philip Morris International (PMI) being barred from importing its Iqos consumables into the US
Altria has posted positive numbers for the last quarter of 2020 despite the coronavirus pandemic, with a good performance for its oral portfolio but unknown figures for Iqos in the US
Altria has reported net revenue to be down by 3.8% in Q2 2020 due to the decrease of the traditional tobacco business, though a further drop was prevented thanks to the good performance of its smokeless products in the US
This report covers the US role as a modern oral tobacco product player, examining snus, tobacco-free nicotine pouches and all-free products
The Altria Group has filed a lawsuit for patent infringement against RJ Reynolds Vapor Co, a subsidiary of Reynolds American, over its Velo smokeless product
Altria has submitted premarket tobacco product applications (PMTAs) to the US Food and Drug Administration (FDA) for 35 varieties of its On! nicotine pouches
Big Tobacco manufacturers are expecting the effects of COVID-19 to hit hard in the second half of the year, despite a strong performance in the first quarter
US tobacco giant Altria has appointed Billy Gifford as CEO. Gifford, previously vice-chairman and CFO, steps up to take over as CEO from Howard Willard, who is retiring after 28 years with the company
The investment value of Altria in e-cig company Juul fell by 65% in almost a year due to the recent developments in the US affecting the brand
Altria’s global net revenues rose 0.3% year-on-year in the third quarter of 2019 to $6.86bn, primarily due to higher net revenues in the smokeless products segment
TobaccoIntelligence considers the effects the possible re-merger of Philip Morris International (PMI) and Altria might have on the combustible and alternatives markets in the US and beyond
US tobacco company Altria has revised its expectations for the US cigarette industry downwards, with a predicted decline up to 6% through 2023
The US FDA has given its approval for Philip Morris International (PMI)’s IQOS in the US, along with its associated consumables ― the first heated-tobacco products to be so approved
The 2018 results from the Altria Group revealed a slump in sales of combustibles. The company is now turning its attention to alternative sectors such as cannabis and Juul, and preparing for the US launch of IQOS
British American Tobacco (BAT) may get two heated-tobacco products onto the US market before IQOS can be launched there, thanks to its decision to take a different route to FDA approval
As tobacco giants Philip Morris International (PMI) and Japan Tobacco (JT) have been hit by falling tobacco sales, revenues from their e-cigarette and heat-not-burn (HnB) portfolios have increased
Big Tobacco is moving towards a smoke-free future, with all the leading companies indicating a focus in 2018 on next generation products, whether e-cigarettes or heated tobacco products
A move by the US FDA to reduce the nicotine content in cigarettes to non-addictive levels could encourage Big Tobacco to put yet more effort into alternatives
Altria is set to take a digital approach to launching its iQOS heat-not-burn product in the U.S. but there will be significant costs along the way.